Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05699226 · ClinicalTrials.gov registry record · NA
Amplitude Titration to Improve ECT Clinical Outcomes
A NA study of Depression and Cognitive Change, sponsored by University of New Mexi.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05699226: Recruiting NA study of Depression and Cognitive Change, sponsored by University of New Mexi.
NCT05699226 is a NA study of Depression and Cognitive Change that is actively recruiting participants, run by University of New Mexi. The registered enrollment target is 50 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05699226, a NA study of Depression and Cognitive Change, is actively recruiting participants, sponsored by University of New Mexi.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
Primary Outcome
Depression severity, scores from 0 to 84, higher scores indicate more depression severity
Conditions Studied
Interventions
- DEVICE Soterix Medical Incorporated 4x1 adapter
- DEVICE Traditional ECT device
Study Locations (1)
New Mexico
- University of New Mexico Health Science Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2028-01-01 |
| Phase | NA |
What NCT05699226 shows while recruiting
NCT05699226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Soterix Medical Incorporated 4x1 adapter is the first listed.
NCT05699226 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT05699226 about?
NCT05699226 is a clinical study titled "Amplitude Titration to Improve ECT Clinical Outcomes". A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm...
What is the current status of trial NCT05699226?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-09-14. Estimated completion is 2028-01-01.
What conditions does trial NCT05699226 study?
This clinical trial studies the following conditions: Depression, Cognitive Change, ECT.
What interventions are being tested in trial NCT05699226?
The interventions under investigation include: Soterix Medical Incorporated 4x1 adapter (DEVICE), Traditional ECT device (DEVICE).
Who is sponsoring clinical trial NCT05699226?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05699226 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05699226's enrollment target sits among peer trials
50 468th of 679 higher than 199 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy